Micro-X
Market Cap
AU$54.5m
Last Updated
2019/10/21 10:40 UTC
Data Sources
Company Financials +
Executive Summary
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia.
Snowflake
Fundamentals
Exceptional growth potential with weak fundamentals.
Share Price & News
How has Micro-X's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
MX1
2.4%
AU Medical Equipment
-0.2%
AU Market
1 Year Return
-22.0%
MX1
31.8%
AU Medical Equipment
10.5%
AU Market
Return vs Industry: MX1 underperformed the Australian Medical Equipment industry which returned 31.8% over the past year.
Return vs Market: MX1 underperformed the Australian Market which returned 10.5% over the past year.
Shareholder returns
| MX1 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 2.4% | -0.2% |
| 30 Day | 1.6% | 3.1% | -1.4% |
| 90 Day | -3.0% | 3.4% | -1.0% |
| 1 Year | -22.0%-22.0% | 34.1%31.8% | 16.9%10.5% |
| 3 Year | -28.3%-28.9% | 52.9%46.2% | 36.9%18.6% |
| 5 Year | n/a | 143.7%124.0% | 50.2%16.2% |
Price Volatility Vs. Market
How volatile is Micro-X's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Is Micro-X Limited's (ASX:MX1) CEO Pay Justified?2 months ago | Simply Wall St
What Kind Of Share Price Volatility Should You Expect For Micro-X Limited (ASX:MX1)?3 months ago | Simply Wall St
How Much Of Micro-X Limited (ASX:MX1) Do Insiders Own?Valuation
Is Micro-X undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Micro-X is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Micro-X has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at Micro-X's' forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Micro-X regulatory filings.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is Micro-X forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
94.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MX1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MX1 is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: MX1's loss is forecast to worsen by 0% next year.
Revenue vs Market: MX1's revenue (80.6% per year) is forecast to grow faster than the Australian market (3.6% per year).
High Growth Revenue: MX1's revenue (80.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MX1's Return on Equity is forecast to be very high in 3 years time (219.7%).
Next Steps
Past Performance
How has Micro-X performed over the past 5 years?
-14.5%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: MX1 is unprofitable, and losses have increased over the past 5 years at a rate of -14.5% per year.
Accelerating Growth: Unable to compare MX1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MX1 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.5%).
Return on Equity
High ROE: MX1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
ROA vs Industry: MX1 is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: MX1 is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Micro-X's financial position?
Financial Position Analysis
Short Term Liabilities: MX1 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MX1 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MX1 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MX1's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Inventory Level: MX1 has a high level of physical assets or inventory.
Debt Coverage by Assets: MX1 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MX1 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MX1 has less than a year of cash runway if free cash flow continues to grow at historical rates of 10% each year.
Next Steps
Dividend
What is Micro-X's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate MX1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MX1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if MX1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MX1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MX1's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
What is the CEO of Micro-X's salary, the management and board of directors tenure and is there insider trading?
4.2yrs
Average board tenure
CEO
Peter Rowland 0
5.1yrs
Tenure
AU$303,863
Compensation
Mr. Peter Robin Rowland, BSc., MBA, MIET, CEng, FAICD, serves as Managing Director and Executive Director of Micro-X Limited. Mr. Rowland is a laser industry veteran with 25 years' experience in engineerin ...
CEO Compensation Analysis
Compensation vs. Market: Peter's total compensation ($USD208.03K) is about average for companies of similar size in the Australian market ($USD259.85K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Board Age and Tenure
4.2yrs
Average Tenure
Experienced Board: MX1's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Peter Rowland
MD & Executive Director
- Tenure: 5.1yrs
- Compensation: AU$303.86k
Georgina Carpendale
CFO & Company Secretary
- Tenure: 3.3yrs
- Compensation: AU$183.20k
Brian Gonzales
Chief Imaging Scientist
- Tenure: 0yrs
Board Members
Yasmin King
Non-Executive Director
- Tenure: 2.8yrs
- Compensation: AU$50.81k
Peter Rowland
MD & Executive Director
- Tenure: 5.1yrs
- Compensation: AU$303.86k
Patrick O'Brien
Non Executive Chairman
- Tenure: 4.2yrs
- Compensation: AU$64.35k
Alexander Gosling
Non-Executive Director
- Tenure: 4.2yrs
- Compensation: AU$42.90k
Company Information
Micro-X Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Micro-X Limited
- Ticker: MX1
- Exchange: ASX
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$54.457m
- Shares outstanding: 165.02m
- Website: https://www.micro-x.com
Location
- Micro-X Limited
- A14, 6 MAB Eastern Promenade
- 1284 South Road
- Tonsley
- South Australia
- 5042
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MX1 | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Dec 2015 |
| MX1 | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Dec 2015 |
Biography
Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The com ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/21 10:40 |
| End of Day Share Price | 2019/10/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.